Yamaguchi K, Tanaka M, Kitagawa N, Kotake T, Yanagi S, Ito H
Department of urology, Teikyo University School of Medicine, Ichihara Hospital.
Hinyokika Kiyo. 1989 Jun;35(6):987-91.
Prostate-specific antigen (PA), gamma-seminoprotein (gamma-Sm) and prostatic acid phosphatase (PAP) have been evaluated in patients with prostate cancer, benign prostatic hyperplasia (BPH), chronic prostatitis and acute prostatitis. PA has proved to be diagnostically more sensitive than PAP and gamma-Sm for the detection of prostatic cancer. Although PA may be elevated more frequently than PAP and gamma-Sm in patients with BPH, there are possibilities that these patients with elevated PA and normal PAP and gamma-Sm may have prostatic cancer or precancerous conditions not detectable in our routine diagnostic procedures. We report two cases of prostatic cancer with persistently elevated PA and diagnosed after repeated biopsies. Our data suggest that PA is a sensitive and useful tumor marker for the diagnosis of prostatic cancer. PAP and gamma-Sm in combination with PA may serve as more useful for differential diagnosis and confirmation of prostatic cancer.
已对前列腺癌、良性前列腺增生(BPH)、慢性前列腺炎和急性前列腺炎患者的前列腺特异性抗原(PA)、γ-精蛋白(γ-Sm)和前列腺酸性磷酸酶(PAP)进行了评估。事实证明,PA在检测前列腺癌方面比PAP和γ-Sm在诊断上更敏感。虽然在BPH患者中PA升高的频率可能比PAP和γ-Sm更高,但这些PA升高而PAP和γ-Sm正常的患者有可能患有前列腺癌或癌前病变,而这些病变在我们的常规诊断程序中无法检测到。我们报告了2例PA持续升高且经多次活检后确诊的前列腺癌病例。我们的数据表明,PA是诊断前列腺癌的一种敏感且有用的肿瘤标志物。PAP和γ-Sm与PA联合使用可能对前列腺癌的鉴别诊断和确诊更有用。